Corvus Pharmaceuticals (NASDAQ:CRVS) Price Target Raised to $14.00

Corvus Pharmaceuticals (NASDAQ:CRVS) had its price target hoisted by Oppenheimer from $8.00 to $14.00 in a research report released on Wednesday,Benzinga reports. Oppenheimer currently has an outperform rating on the stock.

Other equities analysts have also recently issued reports about the company. StockNews.com cut Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, October 31st. LADENBURG THALM/SH SH increased their price objective on Corvus Pharmaceuticals from $12.00 to $21.00 and gave the stock a “buy” rating in a research note on Monday, September 16th. Finally, Mizuho raised Corvus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 22nd. One analyst has rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $12.83.

Corvus Pharmaceuticals Trading Down 9.2 %

NASDAQ CRVS traded down $0.82 on Wednesday, reaching $8.05. The company’s stock had a trading volume of 164,312 shares, compared to its average volume of 357,364. The firm has a market cap of $503.53 million, a PE ratio of -8.66 and a beta of 1.05. Corvus Pharmaceuticals has a 52 week low of $1.30 and a 52 week high of $10.00. The business has a 50-day moving average price of $6.66 and a 200 day moving average price of $3.97.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Samlyn Capital LLC increased its holdings in Corvus Pharmaceuticals by 160.7% during the 2nd quarter. Samlyn Capital LLC now owns 6,123,021 shares of the company’s stock valued at $11,144,000 after purchasing an additional 3,774,658 shares in the last quarter. Point72 Asset Management L.P. bought a new stake in shares of Corvus Pharmaceuticals during the second quarter worth $10,855,000. Vanguard Group Inc. increased its stake in shares of Corvus Pharmaceuticals by 10.6% in the first quarter. Vanguard Group Inc. now owns 1,493,357 shares of the company’s stock valued at $2,658,000 after buying an additional 142,724 shares in the last quarter. Marshall Wace LLP bought a new position in shares of Corvus Pharmaceuticals in the second quarter valued at about $136,000. Finally, Cubist Systematic Strategies LLC bought a new position in shares of Corvus Pharmaceuticals in the second quarter valued at about $44,000. 46.64% of the stock is owned by institutional investors and hedge funds.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.